CTOs on the Move

Arkios BioDevelopment Intl

www.arkios.com

 
Arkios BioDevelopment Intl is a Virginia Beach, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.arkios.com
  • 421 S Lynnhaven Rd Ste 101
    Virginia Beach, VA USA 23452
  • Phone: 757.631.2114

Executives

Name Title Contact Details

Similar Companies

ALERT Life Sciences Computing

ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Technologie BiolActis

Technologie BiolActis Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CervoMed

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIPs development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.

Dermavant

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients` lives. The patient is at the heart of everything we do.